Hormonal
Setmelanotide, an MC4R agonist, significantly reduces hunger and improves health-related quality of life in patients with POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).
If you or your child has a confirmed diagnosis of POMC, LEPR, or BBS-related obesity, standard diet and exercise plans are unlikely to resolve the insatiable hunger (hyperphagia) because they don't fix the underlying genetic signaling error. Setmelanotide is an approved targeted therapy that directly addresses this mechanism, significantly reducing hunger scores and improving quality of life in clinical trials. Consult a specialist in rare metabolic disorders to determine eligibility.
Two 52-week, Phase 3 trials showed significant mean [SD] percent reductions from baseline in hunger scores... after ~ 1 year of treatment with setmelanotide in patients with POMC deficiency... or LEPR deficiency... Similarly, in another Phase 3 trial, 62.5% of patients with BBS or Alström syndrome aged ≥ 12 years without cognitive impairment achieved a ≥ 25% decrease from baseline in hunger score... after 52 weeks of setmelanotide treatment
Why this rating
Based on multiple Phase 3 randomized controlled trials (RCTs) with statistically significant results, though sample sizes for some subgroups (e.g., Alström) are small.
Source
Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response
Jesús Argente et al. · Reviews in Endocrine and Metabolic Disorders · 2025
DOI 10.1007/s11154-025-09984-3
More from this paper
- Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.Good
- Leptin replacement therapy is effective for reducing hunger and weight in patients with congenital leptin deficiency (homozygous LEP variants) but is ineffective in patients with defects downstream of the leptin receptor (e.g., POMC, PC1/3, MC4R deficiencies).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →